TRANSCODE THERAPEUTICS INC (RNAZ) Stock Price, Quote, News and Overview
NASDAQ:RNAZ - Nasdaq - US89357L3033 - Common Stock - Currency: USD
RNAZ Quote, Performance and Key Statistics
TRANSCODE THERAPEUTICS INC
NASDAQ:RNAZ (2/7/2025, 8:00:01 PM)
After market: 10.02 +0.16 (+1.62%)9.86
-1.51 (-13.28%)
The current stock price of RNAZ is 9.86 USD. In the past month the price increased by 187.46%. In the past year, price decreased by -57.32%.
RNAZ Latest News and Analysis
Which stocks are moving on Thursday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Thursday's session: top gainers and losers
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Which stocks are moving before the opening bell on Thursday?
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Here are the top movers in Wednesday's session.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
RNAZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 336.82B | ||
| AMGN | AMGEN INC | 14.81 | 157.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 920.24 | 120.86B | ||
| GILD | GILEAD SCIENCES INC | 21.68 | 119.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.56 | 78.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 22.82B | ||
| BIIB | BIOGEN INC | 8.66 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.27 | 15.52B |
Related stock screener links
About RNAZ
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-04-28. The firm is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
Company Info
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS US
CEO: Robert Michael Dudley
Employees: 10
Company Website: https://www.transcodetherapeutics.com/
Investor Relations: https://ir.transcodetherapeutics.com/
Phone: 18573016857
RNAZ FAQ
What is the stock price of RNAZ?
The current stock price of RNAZ is 9.86 USD.
What is the symbol for TRANSCODE THERAPEUTICS INC stock?
The exchange symbol of TRANSCODE THERAPEUTICS INC is RNAZ and it is listed on the Nasdaq exchange.
On which exchange is RNAZ stock listed?
RNAZ stock is listed on the Nasdaq exchange.
Is RNAZ a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RNAZ, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RNAZ.
Does RNAZ stock pay dividends?
RNAZ does not pay a dividend.
What is the Price/Earnings (PE) ratio of RNAZ?
RNAZ does not have a PE ratio as the earnings reported over the last twelve months were negative (-69.7).
What is the Short Interest ratio of RNAZ stock?
The outstanding short interest for RNAZ is 15.56% of its float.
RNAZ Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RNAZ. When comparing the yearly performance of all stocks, RNAZ is a bad performer in the overall market: 94.77% of all stocks are doing better.
RNAZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNAZ. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNAZ Financial Highlights
Over the last trailing twelve months RNAZ reported a non-GAAP Earnings per Share(EPS) of -69.7. The EPS increased by 95.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -204.75% | ||
| ROE | -325.62% | ||
| Debt/Equity | 0 |
RNAZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RNAZ. The Buy consensus is the average rating of analysts ratings from 7 analysts.